Clinical Research Directory

Inclusion Criteria: * All common significant coronary lesions * Target lesion length \>34mm need to be covered with at least 2 devices * Patients eligible for this study must be at least 18 years of age * The patient must fulfil the standard recommendations for percutaneous coronary intervention (PCI), based on the last ESC recommendations within his/ her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment Exclusion Criteria: * Intolerance to sirolimus * Allergy to components of the coating * Pregnancy and lactation * Complete occlusion of the treatment vessel because of an unsuccessfully re-canalized * Cardiogenic shock * Risk of an intraluminal thrombus * Hemorrhagic diathesis or another disorder such as gastro-intestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anti-coagulation therapy * Surgery shortly after myocardial infarction with indications of thrombus or poor coronary flow behavior * Severe allergy to contrast media * Lesions which are untreatable with PCI or other interventional techniques * Patients with an ejection fraction of \< 30 % * Vascular reference diameter \< 2.00 mm * Treatment of the left stem (first section of the left coronary artery) * Indication for a bypass surgery * Contraindication for whichever accompanying medication is necessary